Researchers at University of California at San Francisco (UCSF) and GE Healthcare have developed a new technology that appears to rapidly assess the presence and aggressiveness of prostate tumors in real time, by imaging the tumor’s metabolism. […]
Although some people have called it intriguing, a new “On The Horizon” drug, XL-184, is still very early in its testing. What makes LX184 intriguing is the just released results from a conference in Berlin. In very early testing, 19 of 20 men in a phase I trial showed an improvement in their scans used [...]
Finally, some good news as Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited have announced their intention to start a Phase III clinical trial of TAK-700 in the U.S. for men with advanced prostate cancer. TAK-700, which I have been writing about under the heading of “On the Horizon,” is [...]
Since the approval of Provenge in April of 2010 the pipeline of new potential immunotherapy drugs has swelled. For excellent reasons, many of us are very optimistic about the future. […]
— A New Trial Marks Expanded Phase 3 Development of MDV3100 into Earlier-Stage Disease — Medivation, Inc. and Astellas Pharma Inc. today announced the launch of a second Phase 3 clinical trial of their investigational drug MDV3100. This trial marks the expansion of the Phase 3 development of their novel, triple-acting oral androgen receptor antagonist [...]
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced the publication of results from their randomized Phase 2 trial of custirsen for men with advanced prostate cancer in the September 20, 2010 Journal of Clinical Oncology. According to their announcement, the trial results showed a survival benefit with their investigational agent OGX-011/TV1011 (custirsen) in men with advanced prostate [...]
When Degarelix (FIRMAGON) which is a gonadotrophin-releasing hormone (GnRH) receptor blocker was first approved by the Food and Drug Administration (FDA) I contacted Ferring Pharmaceuticals and spoke with their medical director. I asked if Degarelix could be used as a second line hormone therapy drug after the traditional first line GnRH agonist drugs (Lupron etc.) [...]
Join us for a conversation about treating advanced stage prostate cancer, with James M. McKiernan, M.D. and Joel Nowak, M.A., M.S.W. […]
The use of high-intensity focused ultrasound (HIFU) for the primary treatment of prostate cancer will probably become more common in the very near future. HIFU has been used for many years in Europe and Mexico and has recently been in clinical trials in the United States. HIFU has been a successful method of prostate cancer [...]
Yesterdays Wall Street Journal publish a very important piece by Melinda Beck in their Health Journal (http://tinyurl.com/2dtrrll) . Everyone should go to the piece and read it. The piece, The Prostate Cancer Quandary, has received some play in the prostate community, but its real importance to us has not yet been recognized by our community [...]
